Zeda Yi Sheng (688555) issued a notice on January 10, 2022: CITIC, Huachuang Securities, CSC FINANCIAL CO.,LTD, Western profit Fund, Ping an Capital Management, CITIC Prudential plc Fund, Guolianan Fund, Oriental Alpha Fund, Finance Fund, Huitianfu Fund, Industrial Fund, Jianxin Fund, Tianhong Fund, Soochow Fund, China Finance Fund, HSBC Jinxin Fund, Guohua Life Insurance, Pacific Insurance investigated our company on December 21, 2021.
The main contents of this survey are as follows:Q: excuse me, what is your company's advantage in R & D of formula granules? What are the company's customers in traditional Chinese medicine slices and granules?
Answer: the company's main advantages in carrying out systematic research on traditional Chinese medicine formula granules are as follows: 1. Research started early. As early as 2016, the company began to explore the study of traditional Chinese medicine formula granules. At present, it has a research basis of hundreds of varieties, and has reached cooperation with a number of pilot units. two。 Good technical foundation. The pilot platform set up by the company can meet the magnification and verification, and the relative advantage is obvious. 3. The business chain is complete. The company not only has the research ability of traditional Chinese medicine technology, but also has the information ability of traditional Chinese medicine production, which can help pharmaceutical companies to quickly establish intelligent factory planning after research and development. 4. Colleges and universities are rich in resources. Most of the executives and core technical personnel of the company come from colleges and universities, and they are rich in expert resources and practical experience. The company has been deeply engaged in the traditional Chinese medicine industry for many years, and its current customers in traditional Chinese medicine slices and granules include Jiangsu Kangyuan, Shandong Hongjitang, Hunan Tiandi Hengyi, Harbin No. 4 traditional Chinese Medicine Factory, Hunan Kangerjia and so on.
Q: what is the impact of the New Policy of traditional Chinese Medicine Formula granules on the company's business on November 1, 2021?
Answer: the national standard for prescription granules of traditional Chinese medicine issued by the State Drug Administration on November 1, 2021 fully embodies the quality control characteristics and the whole quality control concept of traditional Chinese medicine, and measures the "consistency" of formula granules and slices decoction on the basis of "standard decoction". Establish a quantity transfer data table and characteristic map control index, realize the comprehensive control of the quality specificity and integrity of formula granules, and improve the overall quality control level of traditional Chinese medicine. After the implementation of the new policy, all national production formula granule pharmaceutical enterprises have been pulled to the same starting line, that is, the original production internal control standards and process procedures need to refer to national standards to re-formulate and complete the record. Due to the large variety of formula particles and the huge research workload, it is difficult for enterprises to complete the national standard formulation and filing in the short term. Therefore, the huge technology outsourcing service market space for GB review and filing research is opened. In addition, the formal implementation of the first and second batch of formula granule variety quality standards also marks the formal landing of the opening of the market policy for the production and sale of formula granules since 2015. The clarity of the policy will enable enterprises to declare provincial standards or national standards more actively, the competition for enterprise standards declaration will be more fierce, and the technical service market will be more active. As early as 2016, the company began to carry out systematic research on traditional Chinese medicine formula granules, including raw material research, standard decoction, small-scale process, pilot-scale verification, quality standard and stability research, etc. Therefore, this policy has a far-reaching positive impact on the company.
Q: which links of process production are involved in pharmaceutical intelligent manufacturing?
Answer: in the process of pharmaceutical intelligent manufacturing, the process production mainly includes but is not limited to the following links: (1) proprietary Chinese medicine: pretreatment, extraction, preparation, internal and external packaging; (2) biological medicine (vaccine): cell culture, chromatography, preparation, internal and external packaging; (3) chemical drugs: raw materials, preparations, internal and external packaging.
Q: at present, what is the degree of informationization of traditional Chinese medicine, chemical medicine and biological medicine?
Answer: according to the current situation of the development of the industry, the degree of informatization in the three fields is not high, and the order from high to low is biological medicine, chemical medicine and traditional Chinese medicine. The Intelligent Manufacturing Development Plan of the 14th five-year Plan jointly issued by the Ministry of Industry and Information Technology and other eight departments in December 2021 also puts forward new requirements for the digital, networked and intelligent manufacturing of the manufacturing industry. in the future, there is a huge space for continuous expansion in the intelligent manufacturing business of chemical and biological drugs or pharmaceutical enterprises of traditional Chinese medicine.
Q: what is the actual case of the company in the field of chemical medicine?
A: the MES&SCADA project, which the company cooperated hand in hand with Pulo Pharmaceutical Co., Ltd., opened a milestone in the informationization of Prolo Pharmaceutical production. At the same time, the project has achieved a new breakthrough in the field of chemical medicine and consolidated the foundation of intelligent manufacturing of chemical medicine. In the whole project, the company is mainly responsible for the implementation of the MES&SCADA system, which will be used in the oral solid preparation production line of Poluo Pharmaceutical Co., Ltd., which will be integrated with the existing WMS and the ongoing ERP and LIMS systems, and will also be integrated with the "black box" engineering data of Zhejiang Province, which will efficiently meet the requirements of regulations and data reliability, realize the complete paperless production of the workshop, and further improve the quality management. Improve the efficiency of production operations and promote the information construction of Pulo Pharmaceutical Industry. The varieties involved mainly include metoprolol succinate sustained-release tablets, bupropion hydrochloride sustained-release tablets, levofloxacin tablets and so on.
Q: what is the reason for the sharp increase in the amount of inventory items in the company's statements in the first three quarters?
A: the inventory shown on the company's balance sheet is mainly for projects under construction. In the current period, the number of projects undertaken by the company has increased and the unit investment has increased, so the amount of inventory has increased greatly compared with the same period last year, combined with the data of the subject of "contract liabilities". That is, the amount collected from sales customers has more than doubled compared with the end of last year, which is a normal phenomenon after the expansion of the company's business scale.
Q: what is the current gross profit margin of the company?
A: as of June 30, 2021, the gross profit margin of the company's overall business is 45.37%, of which the gross profit margin of system integration business is 23.74%, that of customized software sales business is 78.56%, and that of technical services business is 61.97%. The level of the company's gross profit margin is affected by various factors, such as the structure of the products sold, the price of services, the speed of technology renewal, the market competition environment, the cost of human resources and so on.
Q: please talk about the abnormal volatility of the company's stock trading in late December 2021.
A: the daily closing price deviation of the company's shares exceeded 30% for three consecutive trading days on December 23, December 24 and December 27, 2021. According to the relevant provisions of the Shanghai Stock Exchange Trading rules, the Shanghai Stock Exchange Science and Technology Innovation Board Stock Exchange Special regulations, and the Shanghai Stock Exchange Science and Technology Innovation Board Stock Exchange Real-time Monitoring rules (for trial implementation), it belongs to the abnormal fluctuation of stock trading. After the company's self-examination and verification, all the daily business activities of the company are normal; except for the matters that have been disclosed by the company, the actual controller of the company does not have any major matters affecting the abnormal fluctuation of the company's stock trading, there is no other significant information that should be disclosed but not disclosed by the company, and there are no media reports and market rumors that may have a significant impact on the company's stock trading price, nor does it involve the concept of market hot spots. No other major events that may have a great impact on the company's stock price have been found, and the company's directors, supervisors, senior managers and actual controllers do not buy and sell company stocks during the abnormal fluctuation of the company's stock, and so on.
Zeda Yisheng main business: information business
According to the third quarterly report of Zeda Yi Sheng 2021, the company's main income was 212 million yuan, up 29.28% from the same period last year; the net profit was 36.22 million yuan, down 26.2% from the same period last year; and the non-net profit was 32.94 million yuan, down 18.66% from the same period last year. In the third quarter of 2021, the company's main income in a single quarter was 69.7943 million yuan, up 26.63% from the same period last year; net profit in a single quarter was 9.7548 million yuan, down 49.07% from the same period last year The non-net profit in a single quarter was 8.1769 million yuan, down 49.45% from the same period last year; the debt ratio was 21.89%, the investment income was 2.2845 million yuan, the financial expenses were-1.4771 million yuan, and the gross profit margin was 46.25%.
In the last 90 days, the stock was rated by two institutions and two by buy ratings; the average institutional target price was 40.0 in the past 90 days; the net inflow of financing in the past three months was 7.1445 million, resulting in an increase in the financing balance; and the net inflow of securities was 15.4428 million, with an increase in the balance of securities lending. According to the Securities Star valuation analysis tool, Zeda Yi Sheng (688555) has a rating of 2.5 stars for good companies, 1.5 stars for good prices, and 2 stars for comprehensive valuations. (rating range: 1-5 stars, up to 5 stars)